From: Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial
Variables | Main group, n = 208 | Control group, n = 64 | ||
---|---|---|---|---|
Baseline | 24-week | Baseline | 24-week | |
Systolic blood pressure (mmHg) | 154.3 ± 1.22 | 120.4 ± 0.67** | 150.4 ± 1.76 | 128.7 ± 2.17** |
Diastolic blood pressure (mmHg) | 98.7 ± 0.75 | 80.92 ± 0.63** | 98.1 ± 0.98 | 93.2 ± 1.29* |
Hemoglobin (g/L) | 126.5 ± 0.68 | 138.9 ± 0.62** | 127.1 ± 0.71 | 127.4 ± 0.72 |
ESR (mm/Hour) | 23.4 ± 0.64 | 7.66 ± 0.26** | 22.9 ± 0.70 | 24.8 ± 0.75* |
Eosinophilia (%) | 5.35 ± 0.21 | 1.82 ± 0.14** | 5.29 ± 0.29 | 6.08 ± 0.30* |
Glucose (mmol/L) | 8.64 ± 0.19 | 4.50 ± 0.11** | 8.58 ± 0.24 | 6.04 ± 0.21** |
2-hour OGTT (mmol/L) | 14.5 ± 0.28 | 6.7 ± 0.19** | 14.1 ± 0.33 | 8.21 ± 0.42** |
HbA1c (mmol/mol and %) | 52.0 ± 0.68 (6.91 ± 0.09) | 35.0 ± 0.52** (5.39 ± 0.08) | 52.0 ± 1.13 (6.89 ± 0.15) | 46.0 ± 1.15* (6.38 ± 0.16) |
Cholesterol (mmol/L) | 5.82 ± 0.07 | 4.54 ± 0.05** | 5.77 ± 0.09 | 5.47 ± 0.11* |
Triglyceride (g/L) | 2.42 ± 0.08 | 0.81 ± 0.05** | 2.21 ± 0.08 | 1.92 ± 0.12* |
Total Fibrinogen (g/L) | 4.52 ± 0.07 | 2.21 ± 0.06** | 4.58 ± 0.09 | 4.05 ± 0.18* |
MDA (μmol/L) | 48.47 ± 0.68 | 33.48 ± 0.29** | 46.99 ± 0.75 | 50.46 ± 0.79* |
SOD (U/mg) | 53.83 ± 0.54 | 77.71 ± 0.67** | 52.91 ± 0.65 | 56.87 ± 0.97* |
Catalase (U/g) | 22.17 ± 0.42 | 26.44 ± 0.46** | 23.81 ± 0.49 | 25.17 ± 0.68 |
AOPP (μmol/L) | 266.8 ± 12.6 | 181.8 ± 7.8** | 262.4 ± 13.6 | 295.6 ± 13.9* |
Sodium in the urine (mmol/L) | 164.1 ± 2.8 | 32.4 ± 1.9** | 164.1 ± 2.8 | 182.4 ± 3.5** |
Sodium in the blood (mmol/L) | 134.4 ± 0.32 | 143.7 ± 0.38** | 135.1 ± 0.35 | 134.1 ± 0.34* |
HBMD (Units) | 77.83 ± 1.86 | 93.2 ± 1.37** | 78.78 ± 1.92 | 76.87 ± 1.88 |